FDA approves new bladder cancer treatment while leadership changes loom, as medical debates emerge on hyponatremia management, menopause symptoms, and emerging biomarkers for neurodegeneration.

The FDA approved ctDNA-guided atezolizumab for bladder cancer treatment, marking the first approval for urothelial carcinoma since a 2022 withdrawal of accelerated approval, including both IV formulation and atezolizumab with hyaluronidase-tqjs.

The acting head of the FDA's drug center, Tracey Beth Hoeg, is expected to leave the agency following Commissioner Marty Makary's exit, signaling significant leadership turnover at the federal drug regulatory body.

Calls for a meningitis B catch-up vaccination program for young adults are intensifying after a student death in an outbreak in the Reading area, highlighting gaps in immunization coverage.

Medical experts debate whether chronic hyponatremia should be corrected rapidly or slowly, with recent data challenging traditional guidelines recommending slow correction and suggesting rapid correction may yield better outcomes with lower demyelination risk.

Women with abdominal obesity experience a higher burden of menopausal symptoms and exhibit distinct patterns of symptom interrelationships compared to women without abdominal obesity.

Video oculography technology is emerging as a promising early detection tool for atypical Alzheimer's disease by identifying subtle eye movement abnormalities, advancing interest in ocular biomarkers for neurological screening.

Analysis reveals that fewer than one in five anticancer drugs entering pediatric clinical testing advance to phase 3 trials, with even fewer achieving pediatric regulatory approval, highlighting challenges in pediatric oncology drug development.

New trial data indicate that some patients can maintain meaningful weight loss after reducing from the maximum dose of tirzepatide, potentially offering more sustainable and cost-effective weight management options.